Mymetics and PCI Biotech sign a preclinical research collaboration
Epalinges, Switzerland, August 31, 2022, Mymetics Corporation (OTCQB: MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, have entered into a preclinical research collaboration with the aim to explore technological synergies for the possible enhancement of cancer therapy.
The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Press Release | Download |